Oligonucleotide CDMO Market Depth Study, Analysis, Key Drivers, Top Players, Trends and Forecast 2031

The global oligonucleotide CDMO market is emerging as one of the fastest-growing segments within the pharmaceutical outsourcing industry. The market is projected to expand at a CAGR of nearly 15% over the next five years, supported by the rapid advancement of RNA therapeutics, rising outsourcing activities by biotechnology companies, and increasing approvals of oligonucleotide-based drugs. Growing investments in precision medicine, technological progress in oligonucleotide synthesis, and rising demand for scalable GMP manufacturing solutions are further accelerating market growth.

Understanding the Oligonucleotide CDMO Market

Oligonucleotide Contract Development and Manufacturing Organizations (CDMOs) are specialized service providers engaged in the development, synthesis, manufacturing, testing, and commercialization support of oligonucleotide therapeutics. These therapeutics include antisense oligonucleotides (ASOs), small interfering RNA (siRNA), aptamers, microRNA, guide RNA, and other nucleic acid-based therapies.

Key Request a free sample copy or view report summary: https://meditechinsights.com/oligonucleotide-cdmo-market/request-sample/

CDMOs provide a broad range of services including sequence optimization, custom synthesis, analytical testing, purification, conjugation, formulation development, regulatory support, lipid nanoparticle formulation, and fill-finish operations. The increasing complexity of oligonucleotide manufacturing and the stringent regulatory landscape have encouraged pharmaceutical and biotechnology companies to collaborate with experienced outsourcing partners possessing advanced infrastructure and technical expertise.

Rapid Growth of RNA-Based Therapeutics

The growing success of RNA therapeutics is significantly influencing the expansion of the oligonucleotide CDMO market. RNA-based therapies are increasingly progressing from preclinical and early clinical stages toward commercialization. Therapeutics such as antisense oligonucleotides and siRNA molecules are demonstrating promising outcomes across multiple disease areas, including rare genetic disorders, oncology, infectious diseases, and neurological conditions.

Unlike traditional small molecules, oligonucleotide therapies can directly regulate gene expression and target disease-causing genes with high precision. This unique mechanism has positioned oligonucleotides as a critical component of personalized medicine and precision therapeutics.

The rising number of clinical studies involving RNA-based therapies has substantially increased demand for reliable manufacturing capabilities. As products move into later-stage clinical trials, regulatory agencies require consistent product quality, robust analytical characterization, and scalable manufacturing processes. Consequently, pharmaceutical companies are increasingly partnering with specialized CDMOs capable of ensuring compliance with global GMP standards.

Growing Outsourcing Trends Among Biotechnology Companies

Small and mid-sized biotechnology firms are playing a major role in the advancement of oligonucleotide therapeutics. However, most emerging companies lack the infrastructure, expertise, and financial resources required for large-scale GMP manufacturing. This limitation has accelerated outsourcing trends across the industry.

Developing in-house oligonucleotide manufacturing facilities requires significant investment in synthesis platforms, purification systems, regulatory compliance programs, and specialized personnel. In addition, handling hazardous chemicals and maintaining high-purity production standards add operational complexity.

As a result, biotechnology firms are increasingly relying on CDMOs to streamline product development and reduce operational burdens. Outsourcing enables companies to focus on research, innovation, and clinical development while leveraging external manufacturing expertise.

Modern CDMOs offer integrated solutions that include process optimization, analytical testing, conjugation technologies, formulation development, and commercial manufacturing. These services help biotechnology companies accelerate timelines, improve scalability, and reduce development risks.

Increasing Demand for Chemically Modified Oligonucleotides

One of the most important trends shaping the market is the growing use of chemically modified and conjugated oligonucleotides. Pharmaceutical companies are actively exploring lipid conjugation, peptide conjugation, and backbone modification technologies to enhance therapeutic stability, improve delivery efficiency, and increase target specificity.

These advanced oligonucleotide formats require highly sophisticated manufacturing processes and analytical methods. Consequently, CDMOs are expanding their technical capabilities and investing heavily in advanced GMP manufacturing infrastructure.

The increasing complexity of therapeutic molecules is transforming the role of CDMOs from conventional contract manufacturers into strategic development partners. Modern CDMOs now support every stage of product development, including sequence engineering, conjugation chemistry, analytical validation, process optimization, and commercial-scale production.

Technological Advancements Supporting Market Expansion

Technological innovation continues to strengthen the growth potential of the oligonucleotide CDMO market. Advancements in automated synthesis platforms, high-throughput purification systems, and advanced analytical technologies are improving manufacturing efficiency and product consistency.

Innovations in solid-phase synthesis technologies are helping manufacturers reduce production timelines and improve scalability. In addition, advancements in lipid nanoparticle delivery systems and conjugation chemistry are expanding the therapeutic applications of RNA-based drugs.

Digital process monitoring, automation, and AI-driven quality control systems are also improving operational performance across manufacturing facilities. These technologies help CDMOs maintain high purity standards while ensuring compliance with evolving regulatory requirements.

Type Segment Analysis

Based on product type, the global oligonucleotide CDMO market is segmented into antisense oligonucleotides (ASOs), small interfering RNA (siRNA), and other oligonucleotide categories.

The antisense oligonucleotide segment currently dominates the market due to increasing clinical success and commercialization of ASO therapies. These therapies are widely used in the treatment of rare genetic disorders, cancer, and neurological diseases. The growing number of approved ASO products has created strong demand for large-scale GMP manufacturing and high-purity synthesis services.

The siRNA segment is expected to witness the fastest growth during the forecast period. Improvements in GalNAc-conjugate delivery systems, enhanced efficacy, and increasing use in chronic disease treatment are driving demand for siRNA therapeutics.

Other oligonucleotide categories, including mRNA, aptamers, and guide RNA molecules, are also gaining momentum due to rising interest in gene-editing therapies and next-generation RNA technologies.

Regional Outlook

North America continues to dominate the global oligonucleotide CDMO market due to strong pharmaceutical research activity, advanced healthcare infrastructure, and early adoption of innovative therapeutics. The presence of leading CDMO providers and significant investments in RNA-based drug development further strengthen the region’s market position.

The United States remains a major center for oligonucleotide innovation, supported by favorable regulatory frameworks, strong venture capital funding, and increasing clinical research activities.

Europe also represents a significant market, driven by robust biotechnology research, supportive government initiatives, and advanced manufacturing expertise. Countries such as Germany and Switzerland are recognized for their specialized oligonucleotide production capabilities and high-quality manufacturing standards.

Asia Pacific is emerging as the fastest-growing region in the global market. Increasing investments in biotechnology infrastructure, rising outsourcing demand, and competitive manufacturing costs are encouraging pharmaceutical companies to establish partnerships with Asian CDMOs. Countries such as China, South Korea, Japan, and India are witnessing rapid expansion in RNA therapeutics manufacturing capabilities.

Competitive Landscape

The global oligonucleotide CDMO market is highly competitive and includes several established as well as emerging players focusing on expansion, acquisitions, and strategic collaborations to strengthen their market position.

Key Players Operating in the Global Oligonucleotide CDMO Market

• Bachem Holding AG
• Agilent Technologies
• Lonza Group
• Thermo Fisher Scientific
• WuXi AppTec
• ST Pharm Co., Ltd.
• Eurofins Scientific
• PolyPeptide Group
• Ajinomoto Bio-Pharma Services
• Aurigene Pharmaceutical Services Ltd
• Kaneka Eurogentec S.A

Strategic Developments Across the Industry

Leading companies are actively investing in manufacturing expansion and technological innovation to address growing market demand.

WuXi AppTec expanded its research and development capabilities by opening a new R&D center in Changzhou, China. The facility focuses on process development for oligonucleotides, peptides, and complex conjugates while improving integration between development and manufacturing activities.

Lonza announced additional investments in bioconjugation infrastructure at its Visp facility in Switzerland. The company added multipurpose manufacturing suites to increase commercial-scale production capacity and support rising demand for advanced bioconjugates.

Agilent Technologies strengthened its CDMO business through the acquisition of BIOVECTRA for approximately $925 million. This acquisition enhanced Agilent’s capabilities in oligonucleotides, mRNA, CRISPR therapeutics, lipid nanoparticle formulation, and fill-finish services.

Major Market Drivers

• Expansion of the global RNA therapeutics pipeline
• Increasing outsourcing activities among biotechnology companies
• Growing approvals of oligonucleotide-based drugs
• Continuous advancements in synthesis technologies
• Rising focus on rare genetic disorders
• Increasing need for scalable and GMP-compliant manufacturing

Emerging Market Opportunities

• Growing adoption of personalized and precision medicine
• Rising demand for integrated end-to-end CDMO solutions
• Expansion of biotechnology manufacturing in emerging economies
• Increasing investments in RNA technology platforms
• Advancements in conjugated oligonucleotide therapies
• Growing applications in oncology and gene-editing treatments

Get Free Sample Report: https://meditechinsights.com/oligonucleotide-cdmo-market/request-sample/

Future Outlook

The future of the global oligonucleotide CDMO market appears highly promising as RNA therapeutics continue to reshape modern medicine. Growing commercialization of oligonucleotide drugs, increasing investment in precision medicine, and rising clinical activity are expected to create substantial opportunities for CDMOs worldwide.

As therapeutic molecules become more complex and regulatory expectations continue to evolve, pharmaceutical companies will increasingly depend on specialized outsourcing partners with advanced technical expertise and scalable manufacturing infrastructure. CDMOs capable of delivering integrated development solutions, high-quality production standards, and innovative manufacturing technologies will remain well-positioned for long-term growth in this rapidly expanding market.

About Medi-Tech Insights

Medi-Tech Insights is a healthcare-focused business research & insights firm. Our clients include Fortune 500 companies, blue-chip investors & hyper-growth start-ups. We have completed 100+ projects in Digital Health, Healthcare IT, Medical Technology, Medical Devices & Pharma Services in the areas of market assessments, due diligence, competitive intelligence, market sizing and forecasting, pricing analysis & go-to-market strategy. Our methodology includes rigorous secondary research combined with deep-dive interviews with industry-leading CXO, VPs, and key demand/supply side decision-makers.